| Title: | First-line osimertinib in elderly patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer: a retrospective multicenter study (HOT2002) |
| Authors: | Yamamoto, Gaku Browse this author |
| Asahina, Hajime Browse this author |
| Honjo, Osamu Browse this author |
| Sumi, Toshiyuki Browse this author |
| Nakamura, Atsushi Browse this author |
| Ito, Kenichiro Browse this author |
| Kikuchi, Hajime Browse this author |
| Hommura, Fumihiro Browse this author |
| Honda, Ryoichi Browse this author |
| Yokoo, Keiki Browse this author |
| Fujita, Yuka Browse this author |
| Oizumi, Satoshi Browse this author |
| Morita, Ryo Browse this author |
| Ikezawa, Yasuyuki Browse this author |
| Tanaka, Hisashi Browse this author |
| Kimura, Nozomu Browse this author |
| Sasaki, Takaaki Browse this author |
| Sukoh, Noriaki Browse this author |
| Takashina, Taichi Browse this author |
| Harada, Toshiyuki Browse this author |
| Dosaka-Akita, Hirotoshi Browse this author |
| Isobe, Hiroshi Browse this author →KAKEN DB |
| Issue Date: | 30-Nov-2021 |
| Publisher: | Nature Portfolio |
| Journal Title: | Scientific reports |
| Volume: | 11 |
| Issue: | 1 |
| Start Page: | 23140 |
| Publisher DOI: | 10.1038/s41598-021-02561-z |
| Abstract: | Osimertinib is a standard of care therapy for previously untreated epidermal growth factor receptor mutation-positive non-small cell lung cancer. However, limited data exist regarding the efficacy and safety of osimertinib as a first-line therapy for elderly patients aged 75 years or older. To assess the potential clinical benefits of osimertinib in this population, this retrospective multi-institutional observational study included 132 patients with non-small cell lung cancer (age >= 75 years), who received osimertinib as first-line treatment. The proportion of patients with 1-year progression-free survival was 65.8% (95% confidence interval 57.1-73.5). The median progression-free survival was 19.4 (95% confidence interval 15.9-23.9) months. The median overall survival was not reached (95% confidence interval 24.6-not reached). The frequency of pneumonitis was 17.4%, with a grade 3 or higher rate of 9.1%. More than two-thirds of treatment discontinuations due to pneumonitis occurred within 3 months of starting osimertinib, and the prognosis of patients with pneumonitis was unsatisfactory. Osimertinib is one of the effective first-line therapeutic options for patients aged 75 years or older; however, special caution should be exercised due to the potential development of pneumonitis. |
| Type: | article |
| URI: | http://hdl.handle.net/2115/83961 |
| Appears in Collections: | 北海道大学病院 (Hokkaido University Hospital) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
